Compare OSBC & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OSBC | CMPS |
|---|---|---|
| Founded | 1981 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | 2014 | 2020 |
| Metric | OSBC | CMPS |
|---|---|---|
| Price | $25.29 | $13.19 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 8 |
| Target Price | $23.50 | ★ $25.38 |
| AVG Volume (30 Days) | 454.5K | ★ 3.5M |
| Earning Date | 04-22-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.36% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.02 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $25.20 | N/A |
| Revenue Next Year | $3.66 | N/A |
| P/E Ratio | $24.94 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $16.65 | $3.97 |
| 52 Week High | $26.04 | $15.40 |
| Indicator | OSBC | CMPS |
|---|---|---|
| Relative Strength Index (RSI) | 65.83 | 58.17 |
| Support Level | $22.60 | $10.66 |
| Resistance Level | N/A | $14.68 |
| Average True Range (ATR) | 0.49 | 0.71 |
| MACD | 0.02 | 0.23 |
| Stochastic Oscillator | 79.07 | 74.79 |
Old Second Bancorp Inc is a bank holding company. It provides consumer and commercial banking products such as demand, money market, savings, time deposit, and individual retirement as well as commercial, industrial, consumer, and real estate lending, including installment loans, student loans, agricultural loans, lines of credit and overdraft checking, safe deposit operations, trust services, wealth management services, and additional services tailored to the needs of individual customers, corporates, small-medium enterprises. The company has one operating segment, which is community banking. The company's revenue consists of interest, commission, payments, and other income.
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.